Maxim raised the firm’s price target on Nephros (NEPH) to $6 from $4.50 and keeps a Buy rating on the shares. The company’s Q2 results saw revenue, gross margins, and earnings all above consensus estimates, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEPH: